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Abbreviations
NIDDM, non-insulin-dependent diabetes mellitus; IDDM, insu-
lin-dependent diabetes mellitus; LpL, lipoprotein lipase; ITT, in-
sulin tolerance test; GTT, glucose tolerance test; FFA, free fatty
acid; tg, transgenic; apo CIII, apolipoprotein CIII; VLDL, very low
density lipoprotein.
Introduction
Insulin resistance in type 2 diabetic subjects can be provoked by
acquired and/or genetic factors. One of the most important of
these factors is hyperlipidemia together with elevated plasma
FFA levels [1]. An increase in FFA oxidation leads to a reduction
in glucose uptake, oxidation and storage, and an increase in glu-
cose production [2–4]. However, the precise mechanism by
which elevation of FFA impairs glucose use is still controversial.
According to the glucose-fatty acid cycle proposed by Handle 37
years ago, a rise in FFA oxidation increases intramitochondrial
acetyl-CoA/CoA and NADH/NAD+ ratios with a consequent inac-
tivation of pyruvate dehydrogenase. These alterations raise the
citrate concentration, thereby abolishing phosphofructokinase
activity with an accumulation of glucose-6-phosphate, which ul-
timately inhibits hexokinase activity and leads to a decrease in
glucose uptake [5–6]. Alternatively, the increased insulin resist-
ance provoked by the elevation of FFA has been ascribed to the
inhibition of glucose transporters and/or glucose phosphoryla-
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Abstract
In this study, we examined glucose homeostasis and insulin se-
cretion in transgenic mice overexpressing the human apolipo-
protein CIII gene (apo CIII tg). These mice have elevated plasma
levels of triglycerides, FFA and cholesterol compared to control
mice. The body weight, plasma glucose, and insulin levels, glu-
cose disappearance rates, areas under the ipGTT curve for adult
(4–8mo. old) and aged (20–24mo. old) apo CIII tg mice and
the determination of insulin during the ipGTT were not different
from those of control mice. However, an additional elevation of
plasma FFA by treatment with heparin for 2–4 h impaired the
ipGTT responses in apo CIII tg mice compared to saline-treated
mice. The glucose disappearance rate in heparin-treated trans-
genic mice was slightly lower than in heparin-treated controls.
Glucose (22.2mmol/l) stimulated insulin secretion in isolated is-
lets to the same extent in saline-treated control and apo CIII tg
mice. In islets from heparin-treated apo CIII tg mice, the insulin
secretion at 2.8 and 22.2mmol glucose/l was lower than in hep-
arin-treated control mice. In conclusion, hypertriglyceridemia
per se or a mild elevation in FFA did not affect insulin secretion
or insulin resistance in adult or aged apo CIII tg mice. Nonethe-
less, an additional elevation of FFA induced by heparin in hyper-
triglyceridemic mice impaired the ipGTT by reducing insulin se-
cretion.
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tionwith a subsequent reduction in the rate of glucose oxidation
and muscle glycogen synthesis [7,8]. Normal glucose homeosta-
sis is dependent on the interaction between tissue sensitivity to
insulin and insulin secretion. Thus, an increase in the insulin re-
sistance requires progressive increases in the insulin secretion
rate [9]. If the compensatory hyperinsulinemia is not sufficient
to maintain euglycemia, hyperglycemia may occur [1]. On the
other hand, an increase in FFA oxidation by pancreatic B-cells
stimulates insulin secretion by raising the [Ca2+]i associated
with PKC activation [10]. A rise in FFA oxidation in b-cells also
impairs glucose-induced insulin secretion [11–14].
Transgenic mice expressing the human apolipoprotein CIII (apo
CIII tg) exhibit hypertriglyceridemia and elevated plasma choles-
terol and FFA levels [15–17], and are a suitable model for study-
ing the association between hypertriglyceridemia on the one
hand and insulin resistance and secretion on the other [18,19].
However, hypertriglyceridemic transgenic mice are neither insu-
lin-resistant nor hyperinsulinemic [20].
In the present work, we have confirmed and extended the obser-
vation that hypertriglyceridemia per se does not affect insulin re-
sistance in adult (4–8mo) or aged (20–24mo) apo CIII tg mice.
However, additional FFA increases induced by heparin impaired
the ipGTT in transgenic, but not in control mice. This effect is the
result mainly of a reduction in insulin secretion.
Materials and Methods
Materials
Collagenase was purchased from Boehringer. Antiserum against
insulinwas kindly provided by Dr Leclercq-Meyer (Free Universi-
ty of Brussels, Brussels, Belgium). Rat standard insulin was ob-
tained from Novo-Nordisk (Copenhagen) and human recombi-
nant insulin (Humulin R) from Eli Lilly Co. (Indianapolis, IN). Bo-
vine serum albumin (fraction V) and chemicals were from Sigma
Chemical Co. (St. Louis, MO). The anesthetics Rompun and Veta-
narcol were from Bayer S.A. (Germany) and KInig (Brazil),
respectively. Liquemine was obtained from Roche (Brazil).
Animals
Human apo CIII transgenic mice (line 3707) kindly donated by
Dr. Alan R. Tall (Columbia University, NY) were bred in the ani-
mal facilities of the Department of Physiology and Biophysics,
UNICAMP. The experiments involving animals were approved
by the university’s Ethics Committee and were in accordance
with the Guidelines on the Handling and Training of Laboratory
Animals published by the Universities Federation for Animal
Welfare (1992). The mice had access to standard laboratory
chow and water ad libitum and were housed at 22 M 2 8C on a
12 h light/dark cycle. Male and female homozygous apo CIII
transgenic and non-transgenic littermates aged 4–24 months
were used in this study. Blood for measuring plasma glucose
[21], triglyceride [22], cholesterol [23] and insulin [24]was taken
from either the retro-orbital plexus or the tail of anesthetized
mice. FFA measurements were performed using an enzymatic
colorimetric method according to the manufacturer’s instruc-
tions (Wako Chem. USA, Inc., VA).
Methods
Glucose-tolerance test
Intraperitoneal glucose tolerance tests (ipGTT) were performed
at 4–8months or 20–24months of age. After 12–15 h of fasting,
themicewere injectedwith glucose (2 g/kg) of glucose intraperi-
toneally [25]. Blood samples for glucose determination were ob-
tained from the cut tip of the tail at 0, 15, 30, 60 and 120min. The
insulin was determined during the ipGTT at 0, 30 and 120min
after glucose injection. Glucose response during the glucose tol-
erance test was evaluated by estimating the total area under the
glycemia vs. time curves using the trapezoidal method [26].
Insulin-tolerance test
Intraperitoneal (ip) or intravenous (iv) insulin-tolerance tests
(ITT) were performed in fed mice aged 4–8 months. The ipITT
consisted of a bolus intraperitoneal injection of regular insulin
(0.75 U/kg). Blood samples were obtained from the cut tip of the
tail at 0, 15, 30 and 60min for glucose determination [25]. The
ivITT consisted of a bolus injection of regular insulin (0.1 U/kg)
into the inferior cava vein of the anesthetized mice, which had
previously been laparotomized. Blood samples were obtained
from the cut tipp of the tail at 0, 4, 8, 12 and 16min. The rate con-
stant for serum glucose disappearance (Kitt) was calculated from
the formula 0.693/t1/2. The serum glucose t1/2 was calculated
from the slope of the least square analysis of the serum glucose
concentrations from 0–16min after intravenous insulin injec-
tion [27].
Insulin secretion from isolated pancreatic islets
Fasted mice were killed by decapitation, and the pancreas was
removed. Islets were isolated by handpicking after collagenase
digestion of the pancreas. Groups of five islets were first incubat-
ed for 30min at 37 8C in Krebs-bicarbonate buffer containing
2.8mmol glucose/l and equilibrated with 95% O2/5% CO2 at pH
7.4. The solutionwas then replaced with fresh Krebs-bicarbonate
buffer and the islets were further incubated for 1 h with medium
containing 2.8 or 22.2mmol glucose/l. The incubation medium
contained (in mmol/l): NaCl 115, KCl 5, NaHCO3 24, CaCl2 2.56,
MgCl2 1, and BSA 0.3% (w/v) [28]. The insulin released after
15min and 1 h was quantified as previously described [24] using
rat insulin as the standard.
Statistics
The results are presented as the mean M SEM for the number of
mice (n) indicated. When working with islets, n refers to the
number of experiments performed (120 islets per group per
experimental condition, distributed in groups of five islets
each). The data were analyzed by one-way analysis of variance
(ANOVA) followed by the Tukey-Kramer test for individual dif-
ferences between groups. Non-paired t-tests were used when-
ever appropriate, and p < 0.05 indicated a significant difference.
Results
The body weight, plasma glucose and insulin levels (Table 1),
glucose disappearance rate (Fig.1 A) and area under the ipGTT
curve (Fig.1 B) of adult apo CIII tg mice (4–8mo old) were not
different from those of control mice. The mean plasma insulin
levels during ipGTT at 30 and 120min were 0.41 ng/ml M 0.06












































































































0.2 ng/ml M 0.04 for apo CIII tg mice, respectively. These values
were not different between the two groups. However, the plasma
cholesterol, triglyceride and FFA levels of apo CIII tg were higher
than in control mice (Table 1). The differences in triglyceride, FFA
and cholesterol levels between apo CIII tg and control mice per-
sisted in aged animals (20–24mo old), whereas the plasma glu-
cose levels as well as ipGTT values were no different between the
two groups of aged mice.
Heparin significantly increased the plasma FFA levels of control
and apo CIII tg mice. The mean plasma FFA levels 90 to 240min
after heparin administration were 4.3 M 0.2 and 2.8 M 0.14mmol/l
for apo CIII tg and control mice, respectively (n = 10 for both
groups; p < 0.01). These values were significantly higher than
those obtained prior to heparin administration. The administra-
tion of saline did not interfere with the plasma FFA levels in apo
CIII tg mice, but significantly reduced the levels in control mice
at the end of the period of infusion (130–240min, not shown).
The glucose disappearance rates were 3.51 M 0.34%/min (n = 9)
and 3.47 M 0.27%/min (n = 8) for saline-treated apo CIII tg and
control mice, respectively. The corresponding rates for heparin-
treated apo CIII tg and heparin-treated control mice were
2.88 M 0.36%/min (n = 11) and 4.12 M 0.45%/min (n = 10), respec-
tively. Although these values were significantly different
(p < 0.05), they were not different from control or apo CIII tg
mice treated with saline. In addition, the ipGTT showed an
increased area under the glycemic curve comparing heparin-
treated apo CIII tg mice to saline-treated apo CIII tg mice
(18.7 M 1.0mmol/l Q 120min vs. 13.6 M 1.2mmol/l Q 120min;
n = 10 for both groups; p < 0.01; Fig. 2). Since heparin strongly
interferes with the radioimmunoassay, we unable to measured
plasma insulin during ipGTT of the heparin-treated mice.
In another series of experiments, we examined the insulin secre-
tion from isolated islets from both control and transgenic mice
previously treated with saline or heparin. Basal insulin secretion
in the presence of 2.8mmol glucose/l after a 15min (Figs. 3 A, C)
or 1 h incubation (Figs. 3 B, D) was similar in islets from control
and transgenic saline-treated mice. In the presence of
22.2mmol glucose/l, the insulin secretion in control islets in-
creased to 1.6- and 3.0-fold over basal after 15min and 1 h incu-
bation, respectively (p < 0.05 in both groups), whereas the in-
crease in insulin secretion provoked by 22.2mmol glucose/l in is-
Fig. 1 Insulin and glucose tolerance tests in apo CIII tg and control
mice. In A eight fed adult mice received a bolus intraperitoneal injec-
tion of regular insulin (0.75 U/kg). Blood samples were obtained from
the cut tipp of the tail at 0, 15, 30 and 60min for glucose measure-
ments. In B fasted adult mice received glucose (2 g/kg) intraperitone-
ally. Blood samples were obtained from the cut tip of the tail at 0, 15,
30, 60 and 120min for glucose measurements. The points are means +
SE of 8–12 mice.
Fig. 2 Glucose tolerance tests in saline- and heparin-treated apo CIII
tg mice. The mice were treated with three subcutaneous injections of
saline or heparin at 0, 90 and 180min and received glucose (2 g/kg) in-
traperitoneally at 120min. Blood samples were obtained from the cut
tip of the tail at 120, 135, 150, 180 and 240min for glucose measure-
ments. The points are means + SE of 10–11 mice per group.
Table 1 Body weight and plasma glucose, insulin, cholesterol,
triglyceride and FFA levels in fasted control and apo CIII
tg mice
Control Apo CIII tg
Body weight (g) M 29.4  0.5 (15) 30.4  1.0 (15)
F 23.8  1.0 (15) 24.5  1.0 (15)
Glucose (mg/dl) Fasted 89  4.6 (15) 81  2.8 (15)
Fed 135  4.4 (8) 142  2.4 (8)
Insulin (ng/ml ) Fasted 0.17  0.08 (6) 0.15  0.03 (6)
Fed 0.96  0.3 (16) 0.98  0.2 (13)
Cholesterol (mg/dl) 97  4.2 (10) 117  5.4* (10)
Triglycerides (mg/dl) 86  5.5 (10) 573  61* (10)
FFA (mmol/l) 1.3  0.17 (10) 3.0  0.14* (10)












































































































lets from saline-treated apo CIII tg mice was 2.4- and 3.8-fold
after 15min and 1 h, respectively (p < 0.05). In islets from hepa-
rin-treated control mice, the increment in insulin secretion in-
duced by 22.2mmol glucose/l was much higher than that ob-
served in saline-treated control mice, attaining 4.6- and 12-fold
over basal after 15min and 1 h, respectively (p < 0.01, Figs. 3 A,B).
However, glucose-induced insulin secretion in islets from hepa-
rin-treated apo CIII tg mice was not different from islets derived
from saline-treated apo CIII tg mice (Figs. 3 C,D).
Discussion and Conclusion
Type 2 diabetes mellitus is frequently associated with obesity
and hyperlipidemia [1]. Together, these diseases are part of a
pathophysiological state known as the plurimetabolic syndrome,
but the cause-effect relationship between them is unclear [29].
Two main aspects of this syndrome have been extensively ex-
plored during the past 15 years, namely, the insulin resistance
provoked by increased FFA oxidation [2–4] and, more recently,
B-cell lipotoxicity [11,13]. In the present work, we studied glu-
cose homeostasis and insulin secretion in apo CIII tg mice, a
model in which the primary defect is hypertriglyceridemia.
Streptozotocin-induced diabeticmice show increased expression
of apo CIII mRNA. This upregulation of apo CIII is abolished by in-
sulin administration [30]. These findings suggest that overex-
pression of the apo CIII gene could be responsible for the hyper-
triglyceridemia observed in IDDM. Similarly, apo CIII tg mice
have significantly higher plasma triglycerides, cholesterol and
FFA levels than non-transgenic littermate control mice [15–17].
In agreement with previous results [20], glycemia and insulin-
emia in adult (4–8mo old) apo CIII tg mice were similar to those
of the controls. In aged apo CIII tg mice, glycemic control may be
hampered, although the data for 20–24 months-old transgenic
mice were not significantly different from aged non-transgenic
mice. Thus, hypertriglyceridemia with increased plasma FFA, at
least at the levels observed in these apo CIII tg mice, did not af-
fect the glucose homeostasis of adult or agedmice. Insulin resist-
ance has been reported in humans with increased plasma FFA
concentrations produced by the concomitant administration of
triglycerides and heparin [7,31]. Plasma FFA levels in these sub-
jects were significantly lower than those found in apo CIII tg
mice. However, the increase observed after treatment with hep-
arin was much greater in humans – four-fold in contrast to less
than two-fold in transgenic mice. We have no explanation for
this difference between human and hypertriglyceridemic trans-
genic mice, except that the effect of increased plasma FFA con-
centrations on insulin resistance may be species-specific [20]. A
further possibility is that elevated levels of plasma triglycerides,
and in specially FFA, are necessary but not sufficient to provoke
alterations in insulin action in target tissues. We addressed the
latter possibility by provoking an additional increase in plasma
FFA levels through the administration of heparin to control and
transgenic mice. Both groups showed significant increases in
plasma FFA levels compared to those before heparin administra-
tion. A deterioration of glucose homeostasis in transgenic hepa-
rin-treated mice was observed, based on the increased area un-
der the ipGTT curve and the lower Kitt values in these mice com-
pared to the corresponding controls.
Parallel experiments showed that the glucose-induced insulin
secretion by isolated islets incubated for 15min or 1 h was sim-
ilar in control- and transgenic saline-treated mice. However, in
heparin-treated mice, the glucose-induced insulin secretion
after a 15min or 1 h incubation period was significantly higher
than that observed in islets from saline-treated control mice.
Heparin treatment failed to further increase insulin secretion in
apo C III tg mice. Compelling evidence suggests that acute expo-
sure to high concentrations of FFA renders the B-cells more sen-
sitive to glucose [32], whereas a chronic exposure to high levels
of FFA reduces the glucose-stimulation of insulin secretion
[33,34]. The latter situation seems to be the case for apo CIII tg
mice that present chronic high levels of plasma FFA during their
Fig. 3 Glucose stimulation of insulin secre-
tion in islets from saline-and heparin-treated
apo CIII tg and control mice. Groups of five
islets were preincubated for 45min in Krebs-
bicarbonate medium containing 5.6mmol
glucose/l, after which the medium was re-
placed with Krebs solution containing 2.8 or
22.2mmol glucose/l. The columns represent
the cumulative 15min (A,C) and 1 h (B,D)
insulin secretion and are means + SE of 20–
35 groups of islets. Left panels (A,B) and right
panels (C,D) represent control and apo CIII tg
mice, respectively. *p < 0.05 related to re-













































































































life time. Thus, it is conceivable that the inability of the islet to
secrete an additional amount of insulin during a glucose chal-
lenge in apo CIII tg mice explains the impaired GTT in heparin-
treated apo CIII transgenic mice.
The precise mechanism underlying the reduction in insulin sen-
sitivity produced by increased plasma FFA concentrations is not
yet clear. According to the glucose-fatty acid cycle hypothesis, an
increase in FFA oxidation is necessarily to inhibit phosphofructo-
kinase activity and cause the accumulation of glucose-6-phos-
phate, which in turn inhibits hexokinase activity and eventually
reduces glucose uptake [2–4]. An alternative explanation envis-
ages increased FFA concentrations leading to the inhibition of
glucose transport and/or glucose phosphorylation followed by a
reduction in the rate of glucose oxidation and muscle glycogen
synthesis, and finally, a reduction in glucose-6-phosphate accu-
mulation [7,8]. Regardless of the exact mechanism, it is conceiv-
able that an increase in FFA oxidation is always necessary to pro-
voke insulin resistance. Increased levels of apo CIII protein in the
plasma of transgenic mice decrease the fractional catabolic rate
of VLDL-triglycerides and the uptake of particles by tissue [20].
However, the increased levels of triglycerides and FFA in the
plasma of transgenic mice may not necessarily indicate an in-
crease in FFA oxidation. Furthermore, if FFA oxidation is indeed
increased, it is apparently not sufficiently increased to alter cel-
lular metabolism and provoke insulin resistance in apo CIII
transgenic mice. Recently, the presence of LpL was demonstrated
in islets cells. In addition, LpL-deficient mice islets secrete more
insulin than islets from animals with normal LpL activity. These
LpL-deficient mice have higher fasting insulin and lower blood
glucose levels than wild-type mice [35,36].
In conclusion, the additional increase in plasma FFA levels result-
ing from enhanced lipoprotein lipase activity produced by hepa-
rin in apo CIII tg mice may be responsible for the reduced insulin
secretion by islets and the consequently impaired response to
the ipGTT in these transgenic mice.
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